A clinical trial to evaluate if a new combination of anticancer drugs (called inotuzumab ozogamicin and rituximab) can increase the life-span of patients with a particular type of cancer (relapsed/refractory aggressive Non-Hodgkin lymphoma)compared to other anticancer drug combinations

Authors
Category Primary study
Registry of TrialsClinical Trials Registry - India
Year 2011
This article has no abstract
Epistemonikos ID: b4306cdb639e90c1ece6b083e99c6dd847cadf95
First added on: Apr 16, 2025